PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Buy” by Brokerages



  • Summary:

     

    PTC Therapeutics, Inc. (NASDAQ:PTCT) has been given an average rating of “Buy” by the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $56.63.

    PTCT has been the subject of a number of research analyst reports. ValuEngine lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 4th. Zacks Investment Research cut PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 24th. Citigroup set a $6 ...

     

     

    Read Full News: https://rivertonroll.com/news/2020/01/15/ptc-therapeutics-inc-nasdaqptct-given-average-rating-of-buy-by-brokerages-updated-updated.html


Log in to reply